EURETINA Congress 2026: key results and trends

Functional stability was observed nearly twice as frequently in the treatment group (21/108 [19.4%] eyes) compared with the sham group (10/103 [9.7%] eyes), representing a more than twofold increase in the odds of a stable outcome (odds ratio: 2.24; 95% CI: 0.94–5.64; P=0.053).

Tarcocimab met the primary endpoint, with a ≥2-step DRSS improvement observed in 41.1% of tarcocimab-treated eyes compared with 1.4% of sham-treated eyes, representing a 29-fold higher response rate with tarcocimab (p<0.0001).

Adjusted proportion of patients with ≥15-letter improvement in BCVA for pooled MK/SC: 30.2% 0.25 mg, 33.3% 1.0 mg vamikibart vs 9.9% sham.

Through W112, 56.3% and 27.6% from PDS Q24W achieved ≥2-step and ≥3-step DRSS improvement compared with 52.1% and 23.9% in IVT-PDS Q24W.

For BCVA (ETDRS/BRVT), mean improvements in TEs reached –0.17 logMAR at Month 6 and –0.20 logMAR at Months 9 and 12, compared with minimal change in CEs (between 0.02 and −0.03 logMAR), with statistically significant differences TE vs CE at Months 6, 9, and 12 (p≤0.01).

The incidence of IOP- and glaucoma-related TEAEs in the study eye was 5.6% and 4.3% in the pooled aflibercept 8 mg and 2 mg groups, respectively.

At W24, mean BCVA change from baseline was +7.1, +6.9, and +7.3 letters with EYP-1901 2.7 mg, EYP-1901 1.3 mg, and aflibercept, respectively.

At week 52 after switching to faricimab, mean BCVA change was +0.9 letters (95%CI: -0.5 to 2.4, P=0.069), mean CST change was -74.7 µm (95%CI: -95.0 to -54.5, P<0.001), and mean PED height change was -72.5 µm (95%CI: -98.4 to -46.7, P<0.001).

At Day 56, CG-P5 achieved an IRF-free responder rate of 83.3%, compared to 25.0% for placebo and 60.0% for Eylea.